Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06611020
Recruiting Observational

Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia

NCT06611020 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Observational
Started
2020-01-01
Last updated
2024-09-26

Condition(s) studied

Cervical Intraepithelial Neoplasia

Study summary

HPV vaccination has emerged as a strategy to reduce the risk of recurrence oafter excisional treatment. However, only few data are aviable. In this trial the investigators aim to assess the role of HPV vaccination in women traeted for HPV-related lesions

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Treatment of HPV-related disease Exclusion Criteria: * Previous HPV vaccination

Primary outcome measure(s)

  • HPV recurrence — 2 years

Trial sites (2)

FacilityCityRegionStatus
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Lombardy Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Lombardy Recruiting

More Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials in Italy

DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women Recruiting
REtroperitoneal SArcoma Registry: an International Prospective Initiative Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN) Recruiting
A Composite Assay for HER2-positive Early-stage Breast Cancer Management Recruiting
Non-invasive Detection of Breast Cancer by Breath Analysis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06611020 on ClinicalTrials.gov ↗ ← All trials in Italy